No relationship between TNF-α genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: A case-control study and a meta-analysis

AIDS Research and Human Retroviruses

Volumn 27, Issue 2, 2011, Pages 143-152

  Veloso, Sergi ^a,b,c   Olona, Montserrat ^a,b,c   Peraire, Joaquim ^a,b,c   Viladés, Consuelo ^a,b,c   Pardo, Pedro ^b,c,d   Domingo, Pere ^e,f   Asensi, Victor ^g,h   Broch, Montserrat ^b,c,i   Aguilar, Carmen ^b,c,i   López Dupla, Miguel ^a,b,c   Aragonés, Gerard ^b,d   Garcia Pardo, Graciano ^a,b,c   Sirvent, Joan Josep ^a,b,c   Vendrell, Joan ^a,b,c,j   Richart, Cristóbal ^a,b,c,i   Vidal, Francesc ^a,b,c  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^c UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^d HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^h UNIVERSITY OF OVIEDO   (Spain)

ⁱ Instituto de Salud Carlos III   (Spain)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CELL DNA; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

ADULT; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951717673     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0312     Document Type: Article

References (57)

1. Bradley JR: TNF-mediated inflammatory disease. J Pathol 2008;214:149-160. (Pubitemid 351160153)
2. Sethi JK, Hotamisligil GS: The role of TNFa in adipocyte metabolism. Semin Cell Dev Biol 1999;10:19-29.
3. Warne JP: Tumour necrosis factor a: A key regulator of adipose tissue mass. J Endocrinol 2003;177:351-355. (Pubitemid 36722289)
4. Charrière G, Cousin B, Arnaud E, et al.: Preadipocyte conversion to macrophage. J Biol Chem 2003;278:9850-9855.
5. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, and Gougeon ML: Alteration of TNFa+T cells homeostasis following potent antiretroviral therapy. Contribution to the development of HIV-associated lipodystrophy syndrome. Blood 2000;95:3191-3198. (Pubitemid 30321172)
6. Bastard JP, Caron M, Vidal H, et al.: Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002;359:1026-1031. (Pubitemid 34286541)
7. Lihn AS, Richelsen B, Pedersen SB, et al.: Increased expression of TNF-a, IL-6, and IL-8 in HALS: Implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003;285: E1072-E1080. (Pubitemid 37296329)
8. Johnson JA, Albu JB, Engelson ES, et al.: Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004;286: E261-E271. (Pubitemid 38140318)
9. Jan V, Cervera P, Maachi M, et al.: Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004;9:555-564. (Pubitemid 39150213)
10. Vigouroux C, Maachi C, Nguyen TH, et al.: Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003;17:1503-1511. (Pubitemid 36900551)
11. Domingo P, Vidal F, Domingo JC, et al.: Tumor necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: Potential role in subcutaneous adipocyte apoptosis. Eur J Clin Invest 2005;35:771-780. (Pubitemid 41783595)
12. Christeff N, Melchior JC, de Truchis P, Perronne C, and Gougeon ML: Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. Eur J Clin Invest 2002; 32:43-50. (Pubitemid 36228382)
13. Bouma G, Crusius JBA, Oudkerk Pool M, et al.: Secretion of tumour necrosis factor and lymphotoxin in relation to polymorphisms in TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996;43:456-463. (Pubitemid 26104933)
14. Hajeer AH and Hutchinson IV: Influence of TNFa gene polymorphisms on TNFa production and disease. Hum Immunol 2001;62:1191-1199. (Pubitemid 33032271)
15. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, and Duff GW: An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8 and DR3 alleles. J Exp Med 1993;177:557-560. (Pubitemid 23117109)
16. D'Alfonso S and Richiardi PM: A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994;39:150-154. (Pubitemid 23344817)
17. Hamman A, Mantzoros C, Vidal-Puig A, and Flier JS: Genetic variability in the TNF-alpha promoter is not associated with type II diabetes mellitus (NIDDM). Biochem Biophys Res Commun 1995;211:833-839.
18. Vendrell J, Fernández-Real JM, Gutierrez C, et al.: A polymorphism in the promoter of the tumour necrosis factor-a gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis 2003; 167:257-264. (Pubitemid 36773525)
19. Auguet T, Vidal F, López-Dupla M, et al.: A study on the TNF-a system in Caucasian Spanish patients with alcoholic liver disease. Drug Alcohol Depend 2008;92:91-99. (Pubitemid 350218198)
20. Kaluza W, Reuss E, Grossmann S, et al.: Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol 2000;114:1180-1183. (Pubitemid 30415236)
21. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, and Pirmohamed M: TNF-a promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002;16: 2013-2018. (Pubitemid 35205264)
22. Nolan D, Moore C, Castley A, et al.: Tumour necrosis factoralpha gene-238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 2003;17: 121-123. (Pubitemid 36106307)
23. Tarr PE, Taffé P, Bleiber G, et al.: Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005;191:1419-1426. (Pubitemid 40563352)
24. Asensi V, Rego C, Montes H, et al.: IL-1b (+3954C/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome. Genet Med 2008;10:215-223. (Pubitemid 351416819)
25. Saumoy M, López-Dupla M, Veloso S, et al.: A study on the IL-6 system in HIV-1-infected patients. AIDS 2008;22; 893-896.
26. Saumoy M, Veloso S, Alonso-Villaverde C, et al.: PPARg Pro12Ala polymorphism in HIV-1-infected patients with HAART-related lipodystrophy. Curr HIV Res 2009;7: 533-540.
27. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, and Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia and diabetes mellitus: A cohort study. Lancet 1999;353:2093-2099. (Pubitemid 29278477)
28. Christeff N, Melchior JC, de Truchis P, Perronne C, Nuñez EA, and Gougeon M: Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999;13:2251-2260. (Pubitemid 29531444)
29. Ford ES, Giles WH, and Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination. JAMA 2002; 287:356-359. (Pubitemid 34251969)
30. Hadigan C, Meigs JB, Corcoran C, et al.: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-139. (Pubitemid 32150958)
31. Cochran WG: The combination of estimates from different experiments. Biometrics 1954;10:101-129.
32. Davey-Smith G and Egger M: Meta-analyses of randomised controlled trials. Lancet 1997;350:1182.
33. RevMan Analyses Computer Program: Version 1.0 for Windows. The Nordic Cochrane Center, The Cochrane Collaboration, 2003.
34. HIV Lipodystrophy Case Definition Study Group: An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003;361:726-735.
35. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:51-58.
36. Grinspoon S and Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62 (Pubitemid 40075680)
37. Vonkeman HE, Napel CHH, Oeveren-Dybicz AM, and Vermes I: b3-Adrenergic receptor polymorphism and the antiretroviral therapy-related lipodystrophy syndrome. AIDS 2000;14:1463-1464. (Pubitemid 30459527)
38. Fernández-Real JM, Gutiérrez C, Ricart W, et al.: The TNF-a gene Nco I polymorphism influences the relationship among insulin resistance, percent of body fat, and increased serum leptin levels. Diabetes 1997;46:1468-1472. (Pubitemid 27369085)
39. Kubaszek A, Pihlajamäki J, Komarovski V, et al.: Promoter polymorphism of the TNF-a (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. Diabetes 2003;52:1872-1876. (Pubitemid 36792481)
40. Sookoian SC, González C, and Pirola CG: Meta-analysis of the G-308A tumor necrosis factor a gene variant and phenotypes associated with the metabolic syndrome. Obes Res 2005;13:2122-2131.
41. Vendrell J, Gutiérrez C, Pastor R, and Richart C: A tumor necrosis factor-b polymorphism associated with hypertriglyceridemia in non-insulin-dependent diabetes mellitus. Metabolism 1995;44:691-694.
42. Lee SC, Bing Pu Y, Thomas N, et al.: Tumor necrosis factor alpha gene G-308A polymorphism in the metabolic syndrome. Metabolism 2000;49:1021-1024. (Pubitemid 30641439)
43. Arnedo M, Taffé P, Sahli R, et al.: Contribution of 20 single nucleotide polmorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genom 2007;17:755-764. (Pubitemid 47263070)
44. Ioannidis JP, Ntzani EE, Trikalinos TA, and Contopoulos- Ioannidis DG: Replication validity of genetic association studies. Nat Genet 2001;29:306-309. (Pubitemid 33096456)
45. Bonnet E, Genoux A, Bernard J, Fauvel J, Massip P, and Perret B: Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy. Clin Chem Lab Med 2007;45:815-821. (Pubitemid 47041885)
46. Tarr PE and Telenti A: Toxicogenetics of antiretroviral therapy: Genetic factors that contribute to metabolic complications. Antivir Ther 2007;12:999-1013. (Pubitemid 350114980)
47. Hober D, Benyoucef S, Delannoy AS, et al.: High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients. Infection 1996;24:213-217. (Pubitemid 26188676)
48. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht TM, and Busch MP: Elevations of IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV type 1 infection. AIDS Res Human Retroviruses 2006;22:757-762. (Pubitemid 44735002)
49. Haissman JM, Vestergaard LS, Sembuche S, et al.: Plasma cytokine levels in Tanzanian HIV-1-infected adults and the effect of antiretroviral treatment. J Acquir Immune Defic Syndr 2009;52:493-497.
50. Herbelin G and Aziz Khan K: Is HIV infection a TNF receptor signalling-driven disease? Trends Immunol 2007;29:61-67.
51. Khoo SH, Pepper L, Snowden N, et al.: Tumor necrosis factor c2 micro satellite allele is associated with the rate of HIV progression. AIDS 1997;11:423-428. (Pubitemid 27113002)
52. Konenkov VI and Smolnikova MV: Polymorphism of promotor sites of interleukins-4 and-10 and tumour necrosis factor-a genes in HIV-infected patients. Bull Experiment Biol Med 2002;4:389-391. (Pubitemid 35189721)
53. Knuchel MC, Spira TJ, Neumman AU, et al.: Analysis of a biallelic polymorphism in the tumor necrosis factor alpha promoter and HIV type 1 disease progression. AIDS Res Hum Retroviruses 1998;14:305-309. (Pubitemid 28110668)
54. Wang C, Song W, Lovashevsky E, et al.: Cytokine and chemokine gene polymorphisms among ethnically diverse North Americans with HIV-1 infection. J Acquir Immune Defic Syndr 2004;35:446-454. (Pubitemid 38420653)
55. Erikstrup C, Kallestrup P, Zinyama-Gutsire RB, et al.: Reduced mortality and CD4 cell loss among carriers of the interleukin-10-1082G allele in a Zimbabwean cohort of HIV- 1-infected adults. AIDS 2007;21:2283-2291. (Pubitemid 350287454)
56. Brinkmann BM, Keet IP, Miedema F, Verweij CL, and Klein MR: Polymorphisms within the human tumor necrosis factor- alpha porter region in human immunodeficiency virus type-1 seropositive persons. J Infect Dis 1997;175:188-190. (Pubitemid 27020846)
57. Hendel H, Winkler C, An P, et al.: Validation of genetic casecontrol studies in AIDS and aplication to the CX3CR1 polymorphism. J Acquir Immune Defic Syndr 2001;26: 507-511. (Pubitemid 32489033)